Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour

Journal of Clinical Neuroscience

Volumn 17, Issue 1, 2010, Pages 43-49

  Lau, Eddie W F ^a,b   Drummond, Katharine J ^b,c   Ware, Robert E ^a   Drummond, Elizabeth ^a   Hogg, Annette ^a   Ryan, Gail ^a   Grigg, Andrew ^b,c   Callahan, Jason ^a   Hicks, Rodney J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Brain tumour; Cerebral lymphoma; Glioma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACCURACY; ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN TUMOR; CANCER GRADING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICAL DYSPLASIA; DIAGNOSTIC VALUE; ENCEPHALITIS; FEMALE; FOLLOW UP; GLIOMA; HISTOPATHOLOGY; HUMAN; LYMPHOMA; MALE; MENINGIOMA; NEUROBLASTOMA; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOISOTOPES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TYROSINE; YOUNG ADULT;

EID: 72449131038     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.05.009     Document Type: Article

References (21)

1. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 48 (2007) 1468-1481
2. Di Chiro. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987; 22:360-371.
3. Weber W.A., Wester H.J., Grosu A.L., et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27 (2000) 542-549
4. Rau F.C., Weber W.A., Wester H.J., et al. O-(2-[18F]-fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Image 8 (2002) 1039-1046
5. Popperl G., Gotz C., Rachinger W., et al. Value of F-18 fluoroethyl-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Image 31 (2004) 1464-1470
6. Weckesser M., Langen K.J., Rickert C.H., et al. F-18 fluoroethyl-L-tyrosine PET in the clinical evaluation of primary brain tumour. Eur J Nucl Med Mol Image 32 (2005) 422-429
7. Rachinger W., Goetz C., Popperl G., et al. Positron emission tomography with F-18 fluoroethyl-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57 (2005) 505-511
8. Floeth F.W., Pauleit D., Wittsack H.J., et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with F-18 fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 102 (2005) 318-327
9. Pauleit D., Floeth F., Hamacher K., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128 (2005) 678-687
10. Floeth F.W., Pauleit D., Sabel M., et al. Prognostic value of O-(2-[18F]fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48 (2007) 519-527
11. Floeth F.W., Sabel M., Stoffels G., et al. Prognostic value of O-(2-[18F]fluoroethyl)-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 49 (2008) 730-737
12. Rosenfeld S.S., Hoffman J.M., Coleman R.E., et al. Studies of primary central nervous system lymphoma with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Med 33 (1992) 532-536
13. Hoffman J.M., Waskin H.A., Schifter T., et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 34 (1993) 567-575
14. Grosu A.L., Weber W.A., Franz M., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumour volume for stereotactic fractionated radiotherapy. Int J Rad Oncol Biol Phys 63 (2005) 511-519
15. Popperl G., Goldbrunner R., Gildehaus F.J., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Image 32 (2005) 1018-1025
16. Popperl G., Gotz C., Rachinger W., et al. Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Image 33 (2006) 792-800
17. Hamstra D.A., Rehemtulla A., and Ross B.D. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25 (2007) 4104-4109
18. Wong E.T., and Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol 25 (2007) 4705-4706
19. Chen W., Delaloye S., Silverman D.H.S., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25 (2007) 4714-4721
20. Hamstra D.A., Galba'n C.J., Meyer C.R., et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26 (2008) 3387-3394
21. Kwee S.A., Ko J.P., Jiang C.S., et al. Solitary brain lesions enhancing on MR imaging: evaluation with fluorine-18-fluorocholine PET. Radiology 244 (2007) 557-565